Nrx pharmaceuticals to announce new details for planned investigational brilife™ covid-19 vaccine

Radnor, pa., jan. 07, 2022 (globe newswire) -- nrx pharmaceuticals (nasdaq: nrxp), a clinical-stage, biopharmaceutical company, today announced its chairman of the board and chief executive officer, prof jonathan javitt, md, mph, will be presenting updates to the company's business, including new details regarding late-stage trials of the investigational brilife™ covid-19 vaccine at the h.c. wainwright bioconnect virtual conference.
NRXP Ratings Summary
NRXP Quant Ranking